Taysha Gene Therapies’ (TSHA) Market Outperform Rating Reiterated at JMP Securities

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “market outperform” rating reaffirmed by stock analysts at JMP Securities in a report released on Tuesday,Benzinga reports. They currently have a $5.00 target price on the stock. JMP Securities’ target price indicates a potential upside of 136.80% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday. Canaccord Genuity Group reduced their target price on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday. Finally, Chardan Capital reiterated a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, August 13th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $6.38.

Taysha Gene Therapies Stock Performance

Shares of TSHA stock traded up $0.48 on Tuesday, reaching $2.11. The stock had a trading volume of 11,450,453 shares, compared to its average volume of 2,475,920. Taysha Gene Therapies has a 12 month low of $1.19 and a 12 month high of $4.32. The firm has a market capitalization of $432.74 million, a price-to-earnings ratio of -10.40 and a beta of 0.44. The firm’s 50-day moving average is $1.97 and its two-hundred day moving average is $2.39. The company has a quick ratio of 5.22, a current ratio of 5.22 and a debt-to-equity ratio of 0.35.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The company had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $3.62 million. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. During the same period last year, the firm posted ($0.38) earnings per share. On average, research analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently modified their holdings of the business. Bank of New York Mellon Corp acquired a new stake in Taysha Gene Therapies in the second quarter valued at about $1,018,000. SG Americas Securities LLC acquired a new stake in Taysha Gene Therapies in the third quarter valued at approximately $129,000. Rhumbline Advisers acquired a new position in shares of Taysha Gene Therapies during the second quarter worth $413,000. Scientech Research LLC bought a new stake in Taysha Gene Therapies during the 2nd quarter worth $97,000. Finally, The Manufacturers Life Insurance Company raised its position in Taysha Gene Therapies by 109.0% in the second quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company’s stock valued at $298,000 after purchasing an additional 69,487 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.